23:29 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke A team led by NovaGo Therapeutics co-founder Martin Schwab showed inhibition of RTN4 or its receptor S1PR2 could help treat stroke. In mice, levels of RTN4 and S1PR2 were elevated...
00:12 , Jun 7, 2019 |  BC Extra  |  Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

Celgene resubmits NDA for ozanimod   FDA and EMA accepted submissions from Celgene Corp. (NASDAQ:CELG) for ozanimod to treat multiple sclerosis. The PDUFA date for the selective S1PR1 and S1PR5 modulator is March 25, 2020,...
22:39 , Jun 5, 2019 |  BC Extra  |  Company News

BMS brings in Novartis exec to round out post Celgene acquisition team

With the hire of Novartis’ Samit Hirawat, Bristol-Myers gains some of the R&D chops it needs to become less reliant on its blockbuster checkpoint inhibitors. As it nears the close of its acquisition of Celgene...
00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting S1PR1 for neuropathic pain

DISEASE CATEGORY: Neurology INDICATION: Pain Rat and mouse studies suggest S1PR1 inhibitors or modulators could help treat neuropathic pain. In a rat model of neuropathic pain, astrocyte-specific knockout of S1PR1 in the CNS or intrathecal...
21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
00:37 , Mar 27, 2019 |  BC Extra  |  Company News

FDA approves Novartis' Mayzent for MS

FDA's approval of Novartis’ Mayzent siponimod late Tuesday with a broad label could position the multiple sclerosis drug to stand out from a crowded field with its approval for secondary progressive MS, an indication for...
22:56 , Mar 25, 2019 |  BC Extra  |  Company News

Celgene resubmits NDA for MS candidate ozanimod

Celgene said it resubmitted an NDA to FDA for ozanimod to treat relapsing forms of multiple sclerosis. The company submitted earlier this month an MAA to EMA for the selective S1PR1 and S1PR5 modulator. Last...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
21:01 , Mar 15, 2019 |  BC Extra  |  Company News

ICER suggests Novartis' MS therapy siponimod won't be cost-effective

ICER said the price of multiple sclerosis therapy Mayzent siponimod from Novartis would have to reach a monthly net price of $995 to meet its standard cost-effectiveness threshold of $150,000 per QALY. That price would...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...